Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials

Reuters

Jan 12

Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials

Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug met its primary endpoint, achieving a reduction in nasal polyp score (NPS) of -1.8 (p<0.0001), and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% (p=0.03). The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602514234"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602514234\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602514234?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602514234","market":"fut","top_or_hot":-1,"title":"Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug met its primary endpoint, achieving a reduction in nasal polyp score (NPS) of -1.8 (p&lt;0.0001), and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% (p=0.03). The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug met its primary endpoint, achieving a reduction in nasal polyp score (NPS) of -1.8 (p&lt;0.0001), and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% (p=0.03). The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1db9bs:1","article_id":"2602514234","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602514234","pubTimestamp":1768219469,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps . Verekitug met its primary endpoint, achieving a reduction in nasal polyp score  of -1.8 , and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% . The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","UPB":"UpStream Bio Inc."},"translate_title":"Upstream Bio展示了Verekitug在严重呼吸道疾病试验中的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UPB":0.9},"content_text":"Upstream Bio Showcases Verekitug’s Promise in Severe Respiratory Disease Trials\n    \n\n        Upstream Bio Inc. has released a corporate presentation detailing recent progress in its clinical-stage immunology programs focused on severe respiratory diseases. The company highlighted the completion of the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug met its primary endpoint, achieving a reduction in nasal polyp score (NPS) of -1.8 (p<0.0001), and demonstrated key secondary benefits, including a reduction in need for surgery or steroids by 76% (p=0.03). The treatment was generally well tolerated, with no serious adverse events reported. Additional Phase 2 studies are underway, including VALIANT in severe asthma, with top-line results expected in Q1 2026, and VENTURE in COPD, which is currently enrolling participants. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}